摩根士丹利發表研究報告指，威高股份(01066.HK)受到帶量採購(VBP)的骨科產品銷量提升、醫療設備的穩定增長前景、以及預充式註射器的持續產能擴張所推動，將其目標價由9.85元上調至10.6元，評級為「與大市同步」。
《大行報告》大摩上調威高股份(01066.HK)目標價至10.6元 評級「與大市同步」
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.